Cargando…
An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes
Caring for patients with type 2 diabetes mellitus (T2DM) has entered an era with many recent additions to the regimens used to clinically control their hyperglycemia. The most recent class of agents approved by the Food and Drug Administration (FDA) for T2DM is the sodium–glucose-linked transporter...
Autores principales: | Messana, Joseph A, Schwartz, Stanley S, Townsend, Raymond R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322811/ https://www.ncbi.nlm.nih.gov/pubmed/28255241 http://dx.doi.org/10.2147/VHRM.S105721 |
Ejemplares similares
-
Emerging treatments in type 2 diabetes: focus on canagliflozin
por: Rosiak, Marek, et al.
Publicado: (2014) -
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy
por: Karagiannis, Thomas, et al.
Publicado: (2017) -
CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018) -
A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
por: Nardolillo, AnneMarie, et al.
Publicado: (2014) -
SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert, Jochen
Publicado: (2015)